Mergers, Acquisitions and Takeovers Case Study

Nicholas Piramal India Limited : Mergers and Acquisitions

OR

Abstract:
As India moves towards 2005 product patent regime, many Indian firms are scouting for buyouts and acquisitions of the US and European companies. While Ranbaxy, Dr. Reddy's, Wockhardt and others are in the forefront for acquiring such companies, Nicholas Piramal India Ltd. (NPIL), is doing just the opposite. The company is acquiring more Indian than western firms. In the Indian pharma industry, NPIL has made more acquisitions than any other firm. In 2003, NPIL ranked third in the Indian pharmaceutical industry with a market share of 4.4%, next only to market leader GlaxoSmithKline (5.7%) and Ranbaxy (4.7%). By adopting the strategy of mergers and acquisitions (M&As), it intends to become the top player in the Indian pharma industry.

Pedagogical Objectives:

• To discuss NPIL's business strategy of acquiring firms and analyse whether the company's M&A strategy would help it emerge as a leader in the Indian pharmaceutical industry.

Keywords : Nicholas Piramal India Limited; Mergers, Acquisitions, Alliances Case Study ; Ajay Piramal; Joint venture; Mergers and acquisitions; Research and development; Growth strategy; Indian pharmaceutical industry; Blockbuster drugs; GlaxoSmithKline; Rhone Poulenc; Generic competition; Big pharma; Patents and patented drugs; Food and Drug Administration; 1970 Indian Patent Act

Contents : 
Introduction
Nicholas Piramal’s Business Strategy
The Road Ahead